EIF2A and Huntington disease: The activation of the PERK pathway, usually associated with the inhibition of protein translation and synthesis after eIF2α is phosphorylated by PERK, was shown to improve HD symptoms in cells (STHdhQ111/111) and mice (R6/2) when directly activated by the PERK activator MK-28.